Short answer
Esperion Therapeutics, Inc. (ESPR) filed an 8-K current report with the SEC on May 1, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Definitive take-private agreement at $3.16 cash per share plus one CVR, implying immediate liquidity with additional milestone-dependent upside.
Esperion Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Definitive take-private agreement at $3.16 cash per share plus one CVR, implying immediate liquidity with additional milestone-dependent upside
- CVRs offer up to $100 million aggregate: $40 million tied to 2027 bempedoic-acid sales and $60 million tied to bumetanide sales through 2030
- Closing targeted for Q3 2026, subject to stockholder approval, antitrust clearances, and customary conditions
- Deal has no financing condition, with Parent secured equity and debt commitments
- Termination fees: $68,309,078 payable by Parent or $34,154,539 payable by Esperion under specified circumstances
Item 7.01 · Regulation FD Disclosure
- Esperion announced execution of a merger agreement on May 1, 2026
- Transaction details and strategic implications appear in Exhibit 99.1 press release
- Merger announcement introduces potential shareholder value, closing-condition, and transaction-execution considerations
Item EX-99.1 · Exhibit EX-99.1
- ARCHIMED acquisition offers $3.16 per share cash, a 58% premium to April 30, 2026 closing price
- Shareholders receive one non-tradeable CVR with up to $100 million tied to future product sales
- Total equity value reaches approximately $1.1 billion only if commercial milestones are fully achieved
- Closing targeted for third quarter 2026, subject to shareholder and regulatory approvals
- Esperion becomes privately held and Nasdaq listing ends after completion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Esperion Therapeutics, Inc. 8-K filings
Get the next ESPR 8-K as it lands
Follow ESPR for push alerts, or ask the research agent what this filing means.